Literature DB >> 8887721

Determination of 5-fluorouracil in human plasma by a simple and sensitive reversed-phase HPLC method.

R A Coe1, R A Earl, T C Johnson, J W Lee.   

Abstract

A simple and sensitive reversed-phase HPLC method with UV detection was developed and validated for the quantitation of 5-fluorouracil (5-FC) in human plasma. After acidification and salting out, 5-FU was extracted into ethyl acetate and back-extracted into a basic buffer. The extract was adjusted to neutral pH before being injected onto the HPLC column. 5-FU was separated from the matrix components on a YMC ODS-AQ column at 40 degrees C using an aqueous mobile phase of 10 mM potassium phosphate at pH 5.5. A linear gradient of 0-25% methanol wash eluted late peaks, maintained column performance, and increased column stability. The run time was 20 min. The linear range was 25-300 ng ml-1 (r2 > 0.999). The limit of quantitation was 25 ng ml-1, with a signal-to-noise ratio of 23:1. Interday precision and accuracy of quality control samples were 6.2-8.4% relative standard deviation and -0.1(-)+1.9% relative error.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8887721     DOI: 10.1016/0731-7085(96)01832-8

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  4 in total

1.  Noninvasive visualization of in vivo release and intratumoral distribution of surrogate MR contrast agent using the dual MR contrast technique.

Authors:  Yoshinori Onuki; Igor Jacobs; Dmitri Artemov; Yoshinori Kato
Journal:  Biomaterials       Date:  2010-06-26       Impact factor: 12.479

2.  An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.

Authors:  R Goel; E Chouinard; D J Stewart; S Huan; H Hirte; S Stafford; B Waterfield; J Roach; C Lathia; V Agarwal; R Humphrey; W Walsh; S Matthews; L Seymour
Journal:  Invest New Drugs       Date:  2005-01       Impact factor: 3.850

3.  Pharmacokinetic application of a bio-analytical LC-MS method developed for 5-fluorouracil and methotrexate in mouse plasma, brain and urine.

Authors:  Vaishnavi Ganti; Ellen A Walker; Swati Nagar
Journal:  Biomed Chromatogr       Date:  2013-03-12       Impact factor: 1.902

4.  PLGA nanoparticle formulation of RK-33: an RNA helicase inhibitor against DDX3.

Authors:  Guus Martinus Bol; Raheela Khan; Marise Rosa Heerma van Voss; Saritha Tantravedi; Dorian Korz; Yoshinori Kato; Venu Raman
Journal:  Cancer Chemother Pharmacol       Date:  2015-09-02       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.